Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment

NCT03232177 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT03232177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03232177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment
Lead sponsor
Yuhan Corporation
Phase
Phase 4
Overall status
Completed
Start date
June 5, 2017
Completion date
December 5, 2020
Enrollment
70 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia